US2010292453A1PendingUtilityA1
Lectin compositions and methods for modulating an immune response to an antigen
Est. expiryAug 20, 2022(expired)· nominal 20-yr term from priority
A61K 2039/5152A61K 39/0011C12N 2760/16134C07K 2319/00C07K 14/535A61K 2039/55527A61K 2039/55522A61K 38/00A61K 39/145A61K 2039/545C07K 14/005C12N 2760/16034A61K 2039/6031C07K 2319/33A61K 39/39A61K 2039/55516
75
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention also relates to a method of reducing metastases in a subject comprising administering to the subject a composition comprising a multifunctional molecule comprising a first part which is capable of binding to an antigen bearing target and a second part which is capable of binding to a cell.
Claims
exact text as granted — not AI-modified1 . A composition comprising a nucleic acid molecule encoding a fusion polypeptide, said fusion polypeptide comprising
a first amino acid sequence which is selected from: a carbohydrate binding domain of a collectin; a carbohydrate binding domain of a galectin; a carbohydrate binding domain of a C-type lectin; or an amino acid sequence which can bind to a carbohydrate on a glycoprotein, said carbohydrate being chosen from the group: D-mannose, D-glucose, D-fucose, L-fucose, N-acetyl-beta-D-glucosamine, N-acetyl-beta-D-glucosamine, a sialic acid; and
a second amino acid sequence comprising a ligand for a cell surface polypeptide, said ligand being chosen from the group: a ligand for a cytokine receptor, a ligand for CD40, a ligand for an adhesion molecule, a ligand for a defensin receptor, a ligand for a heat shock protein receptor, a ligand for a counterreceptor for a T cell costimulatory molecule.
2 . The composition of claim 1 , wherein said first amino acid sequence is N-terminal to said second amino acid sequence.
3 . The composition of claim 1 , wherein said first amino acid sequence is C-terminal to said second amino acid sequence.
4 . The composition of claim 1 , wherein said first amino acid sequence can bind to a sialic acid on a glycoprotein, said sialic acid comprising at least one of the following carbohydrate structures: N-acetylneuraminic acid, alpha-NeuNAc-[2->6]-Gal, alpha-NeuNAc-[2->6]-GalNAc, alpha-NeuNAc-[2->3]-Gal.
5 . The composition of claim 1 , wherein said first amino acid sequence comprises a carbohydrate-binding domain of a naturally occurring lectin.
6 . The composition of claim 1 , wherein said first amino acid sequence comprises at least about 10 contiguous amino acids of a hemagglutinin.
7 . The composition of claim 6 , wherein said hemagglutinin is an influenza virus hemagglutinin.
8 . The composition of claim 7 , wherein said contiguous amino acids of an influenza hemagglutinin are contiguous amino acids of an influenza hemagglutinin HA1 domain.
9 . The composition of claim 7 , wherein said influenza virus is an influenza A virus.
10 . The composition of claim 7 , wherein said influenza virus is of a subtype that infects humans.
11 . The composition of claim 9 , wherein said influenza virus is of an H1 subtype.
12 . The composition of claim 11 , wherein said influenza virus is from the strain A/PR/8/34.
13 . The composition of claim 9 , wherein said influenza virus is of an H2 or H3 subtype.
14 . The composition of claim 7 , wherein said influenza virus is of a subtype that does not infect humans.
15 . The composition of claim 1 , wherein said ligand for a cell surface polypeptide is a ligand for a mammalian cell surface polypeptide.
16 . The composition of claim 15 , wherein said ligand for a cell surface polypeptide is a ligand for a mouse cell surface polypeptide.
17 . The composition of claim 15 , wherein said ligand for a cell surface polypeptide is a ligand for a human cell surface polypeptide.
18 . The composition of claim 1 , wherein said ligand for a cell surface polypeptide is a ligand for a cell surface polypeptide of a leukocyte.
19 . The composition of claim 1 , wherein said ligand for a cell surface polypeptide is a ligand for a cell surface polypeptide of an antigen presenting cell.
20 . The composition of claim 19 , wherein said ligand for a cell surface polypeptide is a ligand for a cell surface polypeptide of a professional antigen presenting cell.
21 . The composition of claim 1 , wherein said ligand for a cell surface polypeptide is a ligand for a cell surface polypeptide of a dendritic cell.
22 . The composition of claim 1 , wherein said ligand for a cell surface polypeptide is a ligand for a mouse GM-CSF receptor.
23 . The composition of claim 1 , wherein said ligand for a cell surface polypeptide comprises at least about five contiguous amino acids of a mouse GM-CSF.
24 . The composition of claim 1 , wherein said ligand for a cell surface polypeptide comprises a mouse GM-CSF.
25 . The composition of claim 1 , wherein said ligand for a cell surface polypeptide is a ligand for a human GM-CSF receptor.
26 . The composition of claim 1 , wherein said ligand for a cell surface polypeptide comprises at least about five contiguous amino acids of a human GM-CSF.
27 . The composition of claim 1 , wherein said ligand for a cell surface polypeptide comprises a human GM-CSF.
28 . The composition of claim 1 , wherein said ligand for a cell surface polypeptide is a ligand for a receptor for an interleukin.
29 . The composition of claim 1 , wherein said ligand for a cell surface polypeptide is a ligand for a receptor for a mouse interleukin.
30 . The composition of claim 1 , wherein said ligand for a cell surface polypeptide is a ligand for a receptor for a human interleukin.
31 . The composition of claim 28 , wherein said interleukin is chosen from the group: IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-19, IL-20, IL-21, IL-22, IL-23, IL-24, IL-25.
32 . The composition of claim 1 , wherein said ligand for a cell surface polypeptide comprises at least about 5 contiguous amino acids of an interleukin.
33 . The composition of claim 32 , wherein said interleukin is chosen from the group: IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-19, IL-20, IL-21, IL-22, IL-23, IL-24, IL-25.
34 . The composition of claim 1 , wherein said ligand for a cell surface polypeptide comprises an interleukin.
35 . The composition of claim 34 , wherein said interleukin is chosen from the group: IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-19, IL-20, IL-21, IL-22, IL-23, IL-24, IL-25.
36 . The composition of claim 1 , wherein said ligand for a cell surface polypeptide is a ligand for a receptor for a chemokine.
37 . The composition of claim 1 , wherein said ligand for a cell surface polypeptide is a ligand for a receptor for a mouse chemokine.
38 . The composition of claim 1 , wherein said ligand for a cell surface polypeptide is a ligand for a receptor for a human chemokine.
39 . The composition of claim 36 , wherein said chemokine is a C—C cytokine.
40 . The composition of claim 36 , wherein said chemokine is a C—X—C cytokine.
41 . The composition of claim 36 , wherein said cell surface polypeptide is chosen from the group: CXCR-1, CXCR-2, CXCR-3, CXCR-4, CCR-1, CCR-2, CCR-3, CCR-4, CCR-5, CCR-6, CCR-7, CCR-8.
42 . The composition of claim 36 , wherein said chemokine is chosen from the group: 9E3, AMCF, beta-thromboglobulin, ENA-78, eotaxin, eotaxin-2, IP-10, KC, LIX, mig, MGSA, mob-1, NAP-2, NAP-3, NAP-4, PBSF, MGSA, mouse KC, MIP-2, MIP-1 alpha, NAP-2, ENA-78, GCP-2, ACT-2, C10, CCF18, DC-CK1, ELC, Exodus, FIC, GDCF, GDCF-2, HC-21, HCC-1, 1-309, JE, LAG-1, MARC, MCAF, MCP-1, MCP-2, MCP-3, MCP-4, MCP-5, MRP-2, RANTES SDF, TARC, ATAC, Ltn, SCM-1, neurotactin.
43 . The composition of claim 1 , wherein said ligand for a cell surface polypeptide comprises at least about 5 contiguous amino acids of a chemokine.
44 . The composition of claim 43 , wherein said chemokine is chosen from the group: 9E3, AMCF, beta-thromboglobulin, ENA-78, eotaxin, eotaxin-2, IP-10, KC, LIX, mig, MGSA, mob-1, NAP-2, NAP-3, NAP-4, PBSF, MGSA, mouse KC, MIP-2, MIP-1 alpha, NAP-2, ENA-78, GCP-2, ACT-2, C10, CCF18, DC-CK1, ELC, Exodus, FIC, GDCF, GDCF-2, HC-21, HCC-1, 1-309, JE, LAG-1, MARC, MCAF, MCP-1, MCP-2, MCP-3, MCP-4, MCP-5, MRP-2, RANTES SDF, TARC, ATAC, Ltn, SCM-1, neurotactin.
45 . The composition of claim 1 , wherein said ligand for a cell surface polypeptide comprises a chemokine.
46 . The composition of claim 45 , wherein said chemokine is chosen from the group: 9E3, AMCF, beta-thromboglobulin, ENA-78, eotaxin, eotaxin-2, IP-10, KC, LIX, mig, MGSA, mob-1, NAP-2, NAP-3, NAP-4, PBSF, MGSA, mouse KC, MIP-2, MIP-1 alpha, NAP-2, ENA-78, GCP-2, ACT-2, C10, CCF18, DC-CK1, ELC, Exodus, FIC, GDCF, GDCF-2, HC-21, HCC-1, 1-309, JE, LAG-1, MARC, MCAF, MCP-1, MCP-2, MCP-3, MCP-4, MCP-5, MRP-2, RANTES SDF, TARC, ATAC, Ltn, SCM-1, neurotactin.
47 . The composition of claim 1 , wherein said ligand for a cell surface polypeptide is a ligand for a receptor for an interferon.
48 . The composition of claim 1 , wherein said ligand for a cell surface polypeptide is a ligand for a receptor for a mouse interferon.
49 . The composition of claim 1 , wherein said ligand for a cell surface polypeptide is a ligand for a receptor for a human interferon.
50 . The composition of claim 47 , wherein said interferon is chosen from the group: an interferon-alpha, an interferon-beta, an interferon gamma.
51 . The composition of claim 47 , wherein said ligand for a cell surface polypeptide comprises at least about 5 contiguous amino acids of an interferon.
52 . The composition of claim 47 wherein said interferon is chosen from the group: an interferon-alpha, an interferon-beta, an interferon gamma.
53 . The composition of claim 47 , wherein said ligand for a cell surface polypeptide comprises an interferon.
54 . The composition of claim 53 , wherein said interferon is chosen from the group: an interferon-alpha, an interferon-beta, an interferon gamma.
55 . The composition of claim 1 , wherein said ligand for a cell surface polypeptide is a ligand for a mouse TNF-alpha receptor.
56 . The composition of claim 1 , wherein said ligand for a cell surface polypeptide comprises at least about five contiguous amino acids of a mouse TNF-alpha.
57 . The composition of claim 1 , wherein said ligand for a cell surface polypeptide comprises a mouse TNF-alpha.
58 . The composition of claim 1 , wherein said ligand for a cell surface polypeptide is a ligand for a human TNF-alpha receptor.
59 . The composition of claim 1 , wherein said ligand for a cell surface polypeptide comprises at least about five contiguous amino acids of a human TNF-alpha.
60 . The composition of claim 1 , wherein said ligand for a cell surface polypeptide comprises a human TNF-alpha.
61 . The composition of claim 1 , wherein said ligand for a cell surface polypeptide is a ligand for a mouse flt-3 receptor.
62 . The composition of claim 1 , wherein said ligand for a cell surface polypeptide comprises at least about five contiguous amino acids of a mouse flt-3.
63 . The composition of claim 1 , wherein said ligand for a cell surface polypeptide comprises a mouse flt-3.
64 . The composition of claim 1 , wherein said ligand for a cell surface polypeptide is a ligand for a human flt-3 receptor.
65 . The composition of claim 1 , wherein said ligand for a cell surface polypeptide comprises at least about five contiguous amino acids of a human flt-3.
66 . The composition of claim 1 , wherein said ligand for a cell surface polypeptide comprises a human flt-3.
67 . The composition of claim 1 , wherein said encoded fusion polypeptide further comprises a linker interposed between said first and second amino acid sequences.
68 . The composition of claim 67 , wherein said linker has the formula (Gly x Ser) n , wherein n is an integer between 1 and 15, and x is an integer between 1 and 10.
69 . The composition of claim 1 , wherein said encoded fusion polypeptide further comprises a secretory signal sequence.Join the waitlist — get patent alerts
Track US2010292453A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.